Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Short term Debt (2020 - 2025)

Eton Pharmaceuticals' Short term Debt history spans 6 years, with the latest figure at $2.8 million for Q3 2025.

  • For Q3 2025, Short term Debt fell 32.7% year-over-year to $2.8 million; the TTM value through Sep 2025 reached $2.8 million, down 32.7%, while the annual FY2023 figure was $5.4 million, 420.81% up from the prior year.
  • Short term Debt for Q3 2025 was $2.8 million at Eton Pharmaceuticals, roughly flat from $2.8 million in the prior quarter.
  • Across five years, Short term Debt topped out at $5.4 million in Q4 2023 and bottomed at $364000.0 in Q2 2022.
  • The 5-year median for Short term Debt is $1.5 million (2021), against an average of $2.2 million.
  • The largest annual shift saw Short term Debt tumbled 51.4% in 2022 before it surged 420.81% in 2023.
  • A 5-year view of Short term Debt shows it stood at $1.4 million in 2021, then dropped by 27.15% to $1.0 million in 2022, then soared by 420.81% to $5.4 million in 2023, then fell by 23.33% to $4.1 million in 2024, then plummeted by 32.7% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Short term Debt are $2.8 million (Q3 2025), $2.8 million (Q2 2025), and $4.1 million (Q3 2024).